A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

Clinical trial NCT03785925 · COMPLETED

Trial details

NCT number: NCT03785925
Sponsor: Nektar Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Urinary Bladder Neoplasm Neoplasm Metastasis

Start date: 2019-04-29
Primary completion: 2022-02-09
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.